57 related articles for article (PubMed ID: 34540050)
1. Comparing the Daily Versus the Intermittent Regimens of the Anti-Tubercular Chemotherapy in the Initial Intensive Phase in Non-HIV, Sputum Positive, Pulmonary Tuberculosis Patients.
Mandal PK; Mandal A; Bhattacharyya SK
J Clin Diagn Res; 2013 Feb; 7(2):292-5. PubMed ID: 23542708
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction.
Wang TS; Jing LJ
World J Psychiatry; 2024 May; 14(5):644-652. PubMed ID: 38808092
[TBL] [Abstract][Full Text] [Related]
3. Vitamin A Supplementation in Pulmonary Tuberculosis Patients on Acceleration of Sputum Conversion in Medan City.
Sari DK; Marpaung AP; Siagian P; Arrasyid NK
Open Access Maced J Med Sci; 2019 Oct; 7(20):3505-3508. PubMed ID: 32002084
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Chemotherapy Regimen Combined with Levofloxacin in Patients with Pulmonary Tuberculosis Complicated with Type-2 Diabetes.
Luo PP; Wu L; Liu F; Tian YH; Chen LY; Liu YL
Pak J Med Sci; 2023; 39(2):444-449. PubMed ID: 36950412
[TBL] [Abstract][Full Text] [Related]
5. Sleep quality and its associated factors among patients with tuberculosis: A cross-sectional study.
Liu X; Lan H; Bai X; Li Q; Wen Y; Feng M; Tang X
Front Public Health; 2022; 10():1047425. PubMed ID: 36684994
[TBL] [Abstract][Full Text] [Related]
6. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
Wang M; Guan X; Chi Y; Robinson N; Liu JP
Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
[TBL] [Abstract][Full Text] [Related]
7. Influence of anti-tuberculosis drugs plus cycloserine on sputum negative conversion rate, adverse reactions and inflammatory factors in multi-drug resistant tuberculosis.
Gao W; Yang N; Mei X; Zhu X; Hu W; Zeng Y
Am J Transl Res; 2021; 13(8):9332-9339. PubMed ID: 34540050
[TBL] [Abstract][Full Text] [Related]
8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha and interleukin-10 in whole blood is associated with disease progression in pulmonary multidrug-resistant tuberculosis patients.
Eum SY; Jeon BY; Min JH; Kim SC; Cho S; Park SK; Cho SN
Respiration; 2008; 76(3):331-7. PubMed ID: 18212516
[TBL] [Abstract][Full Text] [Related]
10. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multidrug-resistant tuberculosis in Thailand.
Maranetra KN
Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.
van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.
Welekidan LN; Skjerve E; Dejene TA; Gebremichael MW; Brynildsrud O; Agdestein A; Tessema GT; Tønjum T; Yimer SA
PLoS One; 2020; 15(8):e0236362. PubMed ID: 32797053
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
